Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

WaferGen Acquires NGS Library Preparation Business from IntegenX

Published: Tuesday, January 07, 2014
Last Updated: Tuesday, January 07, 2014
Bookmark and Share
Acquisition propels WaferGen to a major player in the NGS sample prep market.

Pursuant to the asset purchase agreement, WaferGen Bio-systems, Inc., through Wafergen, Inc., its wholly owned subsidiary, acquired on January 6, 2014 substantially all of the assets of IntegenX’s product line used in connection with developing, manufacturing, marketing and selling instruments and reagents relating to library preparation for NGS, including the Apollo 324TM instrument and PrepX® reagents.  The purchase price for the acquired business was composed of (1) an up-front cash payment of $2.0 million, (2) a $1.25 million secured promissory note due on January 6, 2017 (repayable early in certain circumstances), (3) up to three earn-out payments payable based on certain revenue thresholds in 2014, 2015 and 2016, respectively, and (4) Wafergen, Inc.’s assumption of certain liabilities related to the acquired business.  Additional information on the transaction can be found in WaferGen’s Report on Form 8-K filed with the SEC on January 6, 2014.

“We are very excited about adding IntegenX’s NGS library prep business to our product portfolio.  It is highly synergistic with our existing products, especially our NGS target enrichment SmartChip TETM offering,” stated Ivan Trifunovich, President and CEO of WaferGen Bio-systems.  “Serving the same customer base, the two products together address a wide spectrum of customer needs in sample preparation for NGS and enable one-stop shopping for laboratories performing targeted sequencing.  The fully automated Apollo 324TM library prep solution has been a market leader in the low to medium throughput NGS market segment with an expanding installed base, serving a diverse set of clients from university research labs, pharmaceutical and agricultural companies, to diagnostic CLIA labs.  It has generated uniformly positive customer feedback for its superior reliability, turnaround and hands-on time, as well as sample quantity input requirement.  We intend to build upon its success with innovative new applications for this system, as well as with integrated products that include the SmartChip TETMplatform.”

Concurrent with the acquisition of the IntegenX assets, and following the Company’s September 2013 fundraise, WaferGen is making additional changes to its Board of Directors, reducing its size from 9 to 7 and adding significant directly-relevant domain knowledge and management experience.  Effective upon the closing of the transaction, Robert Schueren, CEO of IntegenX, joined WaferGen’s Board of Directors.  Mr. Schueren commented, “I am very pleased with the sale of our NGS library prep business to WaferGen, as the product will find a great home for future growth.  IntegenX will continue to focus on its RapidHITTM human DNA identification business, which serves a very different customer base from the Apollo 324TM product line.  I am confident that Apollo’s full potential will be achieved under WaferGen’s leadership, as the Company’s focus is squarely on the rapidly expanding NGS market.  I am excited about joining WaferGen’s Board and I am looking forward to contributing to the Company’s future success.”  Robert Schueren has held leadership positions in life science and diagnostic companies for more than two decades. Since April 2013, Mr. Schueren has been the Chief Executive Officer of IntegenX and a member of its Board of Directors. Previously he was Vice President and General Manager, Genomics for Agilent Technologies (NYSE: A), where he oversaw a several hundred million dollar product portfolio, including the creation and successful commercialization of SureSelectTM.  Prior to joining Agilent in 2010, he was the Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc., a company he joined in 2006.

In addition, the Board appointed William McKenzie as a director, effective December 30, 2013.  William McKenzie has over 25 years of experience building new businesses in the global life sciences and diagnostics sectors. Most recently, Mr. McKenzie served as Vice President and General Manager of Molecular Diagnostics at PerkinElmer, Inc. (NYSE: PKI) from June, 2010 until December 2012. Previously he served in various other senior roles at PerkinElmer after joining the company in 2005, including serving as Business Development Director then Strategic Marketing Director of Molecular Medicine, and then as Global Business Director of Genetic Screening. Prior to PerkinElmer, Mr. McKenzie worked for more than 12 years in positions of increasing responsibility at Millipore.

At the same time, Scott Davidson and Joseph Pesce, representatives of Great Point Partners, stepped down from the Board, effective December 30th, in order to focus their energies on the firm’s other portfolio companies.  In addition, on December 30th, Robert Coradini departed the Board, following his recent appointment to the role of Chairman at MELA Sciences, as did Dr. Timothy Triche, who desires to devote more time to his research and other commercial interests.

Alnoor Shivji, Chairman of WaferGen, said, “I am delighted to have business leaders of Bill McKenzie’s and Bob Schueren’s caliber join our Board.  Their highly relevant life science tools and molecular diagnostic experience will be tremendously helpful in our efforts to build WaferGen into a leader in the NGS field.  The entire Board is looking forward to working with Bill and Bob on broadening our strategic thinking and exploring the best opportunities for growth.  I also want to thank Bob Coradini, Scott Davidson, Joe Pesce and Tim Triche for their outstanding contributions as directors of WaferGen, especially during the transition period when we were realigning and re-energizing the Company.  I wish them great success in their future professional endeavors.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WaferGen & Genentech Collaborate
WaferGen’s SmartChipTM platform has potential to accelerate pharmaceutical drug discovery and development.
Friday, May 08, 2015
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
New Research Advances Genetic Studies in Wildlife Conservation
‘Next-gen’ DNA sequencing of non-invasively collected hair expands field of conservation genetics.
Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms
Researchers at the Aortic Institute at Yale have tested the genomes of more than 100 patients with thoracic aortic aneurysms, a potentially lethal condition, and provided genetically personalized care.
OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Sperm RNA Test May Improve Evaluation of Male Infertility
To help resolve uncertainty—and guide prospective parents to the right fertility treatments—scientists propose the use of a new kind of fertility test. It involves examining sperm RNA by means of next-generation sequencing.
How the Mammoth Got its Wool
Evolutionary change in a gene reconstructed in the lab from the woolly mammoth was part of a suite of adaptations that allowed the mammoth to survive in harsh arctic environments, according to new research.
NuGEN Scientists Screen 400+ Genes for Fusion Events in Single Assay
Breakthrough proves efficacy of new sample preparation method that could accelerate cancer research and development of treatments and diagnostic tests.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!